Zentalis Pharmaceuticals Price To Sales vs. Return On Asset

ZNTL Stock  USD 3.61  0.02  0.55%   
Based on Zentalis Pharmaceuticals' profitability indicators, Zentalis Pharmaceuticals Llc may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Zentalis Pharmaceuticals' ability to earn profits and add value for shareholders. The value of Price To Sales Ratio is estimated to slide to about 23.9 K. The value of Days Sales Outstanding is estimated to slide to about 19.1 K. At this time, Zentalis Pharmaceuticals' Accumulated Other Comprehensive Income is quite stable compared to the past year. Change To Netincome is expected to rise to about 75.4 M this year, although the value of Interest Income will most likely fall to about 469.1 K.
For Zentalis Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Zentalis Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Zentalis Pharmaceuticals Llc utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Zentalis Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Zentalis Pharmaceuticals Llc over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.50)
Revenue Per Share
0.572
Return On Assets
(0.25)
Return On Equity
(0.43)
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Zentalis Pharmaceuticals Return On Asset vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Zentalis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Zentalis Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Zentalis Pharmaceuticals Llc is rated below average in price to sales category among its peers. It is rated below average in return on asset category among its peers . At this time, Zentalis Pharmaceuticals' Price To Sales Ratio is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Zentalis Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Zentalis Return On Asset vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Zentalis Pharmaceuticals

P/S

 = 

MV Per Share

Revenue Per Share

 = 
6.38 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Zentalis Pharmaceuticals

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.25
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Zentalis Return On Asset Comparison

Zentalis Pharmaceuticals is currently under evaluation in return on asset category among its peers.

Zentalis Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Zentalis Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Zentalis Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Zentalis Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Zentalis Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income2.2 M2.3 M
Net Interest Income572.7 K469.1 K
Interest Income572.7 K469.1 K
Operating Income-249 M-236.5 M
Net Loss-286.4 M-272 M
Income Before Tax-276.9 M-263 M
Total Other Income Expense Net-27.9 M-26.5 M
Net Loss-213.1 M-202.5 M
Net Loss-292.2 M-277.6 M
Income Tax Expense-601 K-571 K
Non Operating Income Net Other-14.7 M-13.9 M
Change To Netincome71.8 M75.4 M
Net Loss(4.47)(4.69)
Income Quality 0.71  0.90 
Net Income Per E B T 1.06  0.79 

Zentalis Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Zentalis Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Zentalis Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Zentalis Pharmaceuticals' important profitability drivers and their relationship over time.

Use Zentalis Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zentalis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zentalis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Zentalis Pharmaceuticals Pair Trading

Zentalis Pharmaceuticals Llc Pair Trading Analysis

The ability to find closely correlated positions to Zentalis Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zentalis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zentalis Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zentalis Pharmaceuticals Llc to buy it.
The correlation of Zentalis Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zentalis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zentalis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zentalis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Zentalis Pharmaceuticals position

In addition to having Zentalis Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Advertising Thematic Idea Now

Advertising
Advertising Theme
Companies specializing in advertising, marketing and advertising services. The Advertising theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Advertising Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Zentalis Pharmaceuticals is a strong investment it is important to analyze Zentalis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zentalis Pharmaceuticals' future performance. For an informed investment choice regarding Zentalis Stock, refer to the following important reports:
Check out Your Current Watchlist.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
To fully project Zentalis Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Zentalis Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Zentalis Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Zentalis Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Zentalis Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Zentalis Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Zentalis Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.